SG11201902857SA - Activatable anti-ctla-4 antibodies and uses thereof - Google Patents
Activatable anti-ctla-4 antibodies and uses thereofInfo
- Publication number
- SG11201902857SA SG11201902857SA SG11201902857SA SG11201902857SA SG11201902857SA SG 11201902857S A SG11201902857S A SG 11201902857SA SG 11201902857S A SG11201902857S A SG 11201902857SA SG 11201902857S A SG11201902857S A SG 11201902857SA SG 11201902857S A SG11201902857S A SG 11201902857SA
- Authority
- SG
- Singapore
- Prior art keywords
- ctla
- international
- days post
- california
- post implantation
- Prior art date
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 7
- 238000002513 implantation Methods 0.000 abstract 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 241000237502 Ostreidae Species 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 235000020636 oyster Nutrition 0.000 abstract 3
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000000873 masking effect Effects 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
40 60 Days Post Implantation 'gr ' E 2500- 10/10 TF nE 2500 E 2000- E 2000 E 1500- E 1500 7 , 1000- 0 1000 500- 0 E 500 0 0 20 40 60 Days Post Implantation 8/10 TF 20 40 60 Days Post Implantation rTe E E 0 0 2500 2000 1500 1000 500 0 FIG. 9D YV23 2001 9/10 TF 20 40 60 Days Post Implantation FIG. 9E YV24 2001 2500 2000 1500 1000 500 0 FIG. 9F YV39 2001 2500 2000 1500 1000 500 0 Fsi E E E E C . 7 2500 E 2000 E 1500 0 1000 8 500 E 0 7/10 TF 20 40 60 Days Post Implantation E ‘ E ) o 0 E I- 10/101T 20 40 60 Days Post Implantation (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1111111111110110101011111011110 100111MIONOITEREMOVIO# (10) International Publication Number WO 2018/085555 A8 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 19/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/059740 (22) International Filing Date: 02 November 2017 (02.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/417,212 03 November 2016 (03.11.2016) US (71) Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Rt. 206 & Province Line Road, Princeton, New Jersey 08543 (US). CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: TIPTON, Kimberly Ann; c/o CytomX Thera- peutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). WEST, James William; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DESHPANDE, Shrikant; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). ENGELHARDT, John J.; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). (74) Agent: CALVO, Paul A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washing- ton, District of Columbia 20005 (US). (54) Title: ACTIVATABLE ANTI-CTLA-4 ANTIBODIES AND USES THEREOF FIG. 9A Control mg2a FIG. 9B !pi mg2a (YV1) FIG. 9C YV04 2001 (57) : Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 00 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage O of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the 00 activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated O with anti-CTLA-4 activity outside the tumor. O [Continued on next page] WO 2018/085555 A8 MIDEDIM01101 DIDIRE10111011111111111HHH11111111101111111111 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (48) Date of publication of this corrected version: 31 May 2018 (31.05.2018) (15) Information about Correction: see Notice of 31 May 2018 (31.05.2018)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417212P | 2016-11-03 | 2016-11-03 | |
| PCT/US2017/059740 WO2018085555A1 (en) | 2016-11-03 | 2017-11-02 | Activatable anti-ctla-4 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902857SA true SG11201902857SA (en) | 2019-05-30 |
Family
ID=61132883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902857SA SG11201902857SA (en) | 2016-11-03 | 2017-11-02 | Activatable anti-ctla-4 antibodies and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11117968B2 (en) |
| EP (1) | EP3535300A1 (en) |
| JP (2) | JP7039582B2 (en) |
| KR (2) | KR102584340B1 (en) |
| CN (1) | CN110072890B (en) |
| AR (1) | AR110678A1 (en) |
| AU (1) | AU2017355446A1 (en) |
| BR (1) | BR112019008223A2 (en) |
| CA (1) | CA3042679A1 (en) |
| CL (1) | CL2019001226A1 (en) |
| CO (1) | CO2019004469A2 (en) |
| EA (1) | EA201990875A1 (en) |
| IL (1) | IL265625A (en) |
| MX (1) | MX2019004775A (en) |
| MY (1) | MY200695A (en) |
| PE (1) | PE20191131A1 (en) |
| SG (1) | SG11201902857SA (en) |
| TW (2) | TWI784983B (en) |
| WO (1) | WO2018085555A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118146306A (en) | 2013-09-25 | 2024-06-07 | 西托姆克斯治疗公司 | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| CN114106099B (en) | 2014-01-31 | 2024-05-24 | 西托姆克斯治疗公司 | Substrates and other cleavable moieties for proteolytic enzymes and U-shaped plasminogen activators and methods of use thereof |
| MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
| SG11201902857SA (en) | 2016-11-03 | 2019-05-30 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| KR20230073346A (en) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | Ligand-binding molecule having adjustable ligand binding activity |
| EP3546574A4 (en) | 2016-11-28 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
| BR112019023992A2 (en) | 2017-05-19 | 2020-06-16 | Wuxi Biologics (Shanghai) Co., Ltd. | ANTIBODY OR FRAGMENT FOR BINDING THE ANTIGEN OF THE SAME, ITS PRODUCTION METHOD, ITS USES, AS WELL AS A NUCLEIC ACID MOLECULE, CLONING OR EXPRESSION VECTOR, HOST CELL, HYBRIDOMA, PHARMACEUTICAL AND IMMUNE PHARMACEUTICAL COMPOSITION |
| KR20200086312A (en) | 2017-11-08 | 2020-07-16 | 야페이 상하이 바이오로그 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | Biomolecule conjugates and uses thereof |
| TW201936208A (en) * | 2017-11-28 | 2019-09-16 | 日商中外製藥股份有限公司 | Polypeptide comprising antigen-binding domain and carrying part |
| JP2021518603A (en) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | Systems and Methods for Quantitative Pharmacological Modeling of Activateable Antibody Species in Mammalian Subjects |
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| BR112020023160A2 (en) | 2018-05-14 | 2021-02-02 | Werewolf Therapeutics, Inc. | activable interleukin 2 polypeptides and methods of using these |
| US12077577B2 (en) | 2018-05-30 | 2024-09-03 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| EP3955960A1 (en) | 2019-04-18 | 2022-02-23 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
| CN110498856B (en) * | 2019-09-17 | 2020-08-11 | 浙江玉安康瑞生物科技有限公司 | CTLA-4 monoclonal antibody 5H7 and application thereof in tumor resistance |
| JP2022553851A (en) | 2019-11-08 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | LAG-3 antagonists for the treatment of melanoma |
| EP4076529A1 (en) | 2019-12-19 | 2022-10-26 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| JP7483896B2 (en) * | 2020-01-17 | 2024-05-15 | エショー バイオセラピー， インク． | Pro-Antibodies Reduce Off-Target Toxicity |
| WO2021207657A1 (en) * | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| AR122043A1 (en) | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | DOSAGE AND ADMINISTRATION OF ACTIVABLE ANTI-CTLA-4 ANTIBODY |
| WO2021238932A1 (en) * | 2020-05-26 | 2021-12-02 | 百奥泰生物制药股份有限公司 | Multi-specific antibody and application thereof |
| US11512113B2 (en) | 2020-08-11 | 2022-11-29 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| US11555078B2 (en) | 2020-12-09 | 2023-01-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens |
| WO2022187272A1 (en) * | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
| KR20240024929A (en) | 2021-06-21 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | Use of sucrose, mannitol, and glycine to reduce reconstitution time of high-concentration lyophilized biologic drug products |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| WO2023183923A1 (en) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202426637A (en) | 2022-08-01 | 2024-07-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | Protease-cleavable substrates and methods of use thereof |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| WO2024049203A1 (en) * | 2022-09-02 | 2024-03-07 | 주식회사 시클리드 | Anti-ctla-4 monoclonal antibody and use thereof |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
| EP1071700B1 (en) | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| WO2002030460A2 (en) | 2000-10-09 | 2002-04-18 | Isis Innovation Ltd. | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| CN104530225A (en) | 2002-04-09 | 2015-04-22 | 协和发酵麒麟株式会社 | Cells of which genome is modified |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| KR101291640B1 (en) | 2005-02-18 | 2013-08-05 | 메다렉스, 엘.엘.시. | Monoclonal antibodies against prostate specific membrane antigen(psma) lacking in fucosyl residues |
| JP4361545B2 (en) * | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | Cancer treatment method using human monoclonal antibody and anti-PD-1 antibody alone or in combination with other immunotherapy against Programmed Death 1 (PD-1) |
| RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CA2620886C (en) | 2005-08-31 | 2017-03-14 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| US20090175886A1 (en) | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| WO2007105027A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| AU2007308983B2 (en) | 2006-10-24 | 2012-12-06 | Emergent Product Development Seattle, Llc | A method for increasing antibody-dependent cytotoxicity with castanospermine |
| ES2616355T3 (en) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed death receptor PD-1 |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2240204A1 (en) * | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102076865B (en) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | The antibody reduced for the manufacture of core fucosylation and the method and composition of antibody derivatives |
| HRP20240240T1 (en) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN106995495A (en) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | Modified antibodies composition and its preparation and application |
| RS60033B1 (en) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| JP5826863B2 (en) * | 2011-02-15 | 2015-12-02 | イミュノジェン・インコーポレーテッド | Cytotoxic benzodiazepine derivatives |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CN103842383B (en) | 2011-05-16 | 2017-11-03 | 健能隆医药技术（上海）有限公司 | Polyspecific FAB fusion proteins and its application method |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| IN2014MN02164A (en) | 2012-04-27 | 2015-08-28 | Cytomx Therapeutics Inc | |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112014029883B1 (en) | 2012-05-31 | 2023-10-24 | Sorrento Therapeutics Inc. | ANTI-PD-L1 RECOMBINANT ANTIBODY AND USE OF AN ANTI-PD-L1 RECOMBINANT ANTIBODY |
| BR112014031689A2 (en) | 2012-06-22 | 2017-07-25 | Cytomx Therapeutics Inc | anti-jagged 1 / jagged 2 cross reactive antibodies, activatable anti-jagged antibodies and methods of use |
| PT2992017T (en) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Antibodies directed against programmed death-1 (pd-1) |
| WO2014193973A2 (en) * | 2013-05-28 | 2014-12-04 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| CA2913977C (en) | 2013-05-31 | 2022-11-29 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
| KR102100419B1 (en) | 2013-09-13 | 2020-04-14 | 베이진 스위찰랜드 게엠베하 | Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics |
| US11046975B2 (en) * | 2013-10-07 | 2021-06-29 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
| PT3081576T (en) | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| US10414814B2 (en) | 2014-07-03 | 2019-09-17 | City Of Hope | Tumor-selective CTLA-4 antagonists |
| AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
| SG11201707383PA (en) * | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US10696745B2 (en) | 2015-06-11 | 2020-06-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Anti-PD-L1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| FI3334763T3 (en) | 2015-08-11 | 2024-10-30 | Wuxi Biologics Ireland Ltd | Novel anti-pd-1 antibodies |
| AR105654A1 (en) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH) |
| CN114605548A (en) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | anti-PD-1 antibodies and methods of use thereof |
| CN108367069B (en) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | Bispecific molecules immunoreactive for PD-1 and CTLA-4 and methods of use thereof |
| JP7082051B2 (en) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Interleukin-10 and its use in the production of antigen-specific CD8 + T cells |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| SG11201902857SA (en) | 2016-11-03 | 2019-05-30 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| US11939385B2 (en) | 2017-05-16 | 2024-03-26 | ALX Oncology Inc. | Activatable antibodies and methods of use thereof |
| JP2020531430A (en) | 2017-08-16 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Anti-CTLA4 probody therapy targeting antibodies |
-
2017
- 2017-11-02 SG SG11201902857SA patent/SG11201902857SA/en unknown
- 2017-11-02 BR BR112019008223A patent/BR112019008223A2/en unknown
- 2017-11-02 CN CN201780066620.7A patent/CN110072890B/en active Active
- 2017-11-02 MY MYPI2019002439A patent/MY200695A/en unknown
- 2017-11-02 KR KR1020197015448A patent/KR102584340B1/en active IP Right Grant
- 2017-11-02 JP JP2019523779A patent/JP7039582B2/en active Active
- 2017-11-02 EA EA201990875A patent/EA201990875A1/en unknown
- 2017-11-02 MX MX2019004775A patent/MX2019004775A/en unknown
- 2017-11-02 EP EP17837917.8A patent/EP3535300A1/en active Pending
- 2017-11-02 KR KR1020237032965A patent/KR20230141941A/en not_active Application Discontinuation
- 2017-11-02 US US16/347,522 patent/US11117968B2/en active Active
- 2017-11-02 AU AU2017355446A patent/AU2017355446A1/en active Pending
- 2017-11-02 PE PE2019000902A patent/PE20191131A1/en unknown
- 2017-11-02 CA CA3042679A patent/CA3042679A1/en active Pending
- 2017-11-02 WO PCT/US2017/059740 patent/WO2018085555A1/en active Application Filing
- 2017-11-03 TW TW106138139A patent/TWI784983B/en active
- 2017-11-03 TW TW111141621A patent/TW202334213A/en unknown
- 2017-11-03 AR ARP170103060A patent/AR110678A1/en unknown
-
2019
- 2019-03-26 IL IL265625A patent/IL265625A/en unknown
- 2019-04-30 CO CONC2019/0004469A patent/CO2019004469A2/en unknown
- 2019-05-03 CL CL2019001226A patent/CL2019001226A1/en unknown
-
2021
- 2021-08-11 US US17/399,729 patent/US20220089734A1/en active Pending
-
2022
- 2022-03-09 JP JP2022036450A patent/JP7472183B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR110678A1 (en) | 2019-04-24 |
| KR20190072626A (en) | 2019-06-25 |
| MY200695A (en) | 2024-01-11 |
| TW201819412A (en) | 2018-06-01 |
| MX2019004775A (en) | 2019-08-05 |
| US11117968B2 (en) | 2021-09-14 |
| JP7472183B2 (en) | 2024-04-22 |
| TWI784983B (en) | 2022-12-01 |
| IL265625A (en) | 2019-05-30 |
| CO2019004469A2 (en) | 2019-05-10 |
| WO2018085555A8 (en) | 2018-05-31 |
| WO2018085555A1 (en) | 2018-05-11 |
| CN110072890B (en) | 2022-11-29 |
| KR102584340B1 (en) | 2023-10-10 |
| BR112019008223A2 (en) | 2019-07-16 |
| AU2017355446A1 (en) | 2019-05-02 |
| US20190359714A1 (en) | 2019-11-28 |
| EP3535300A1 (en) | 2019-09-11 |
| US20220089734A1 (en) | 2022-03-24 |
| CL2019001226A1 (en) | 2019-09-13 |
| EA201990875A1 (en) | 2019-09-30 |
| TW202334213A (en) | 2023-09-01 |
| JP7039582B2 (en) | 2022-03-22 |
| CN110072890A (en) | 2019-07-30 |
| KR20230141941A (en) | 2023-10-10 |
| JP2020500016A (en) | 2020-01-09 |
| PE20191131A1 (en) | 2019-09-02 |
| CA3042679A1 (en) | 2018-05-11 |
| JP2022091800A (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201902857SA (en) | Activatable anti-ctla-4 antibodies and uses thereof | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201900026TA (en) | Antibodies against tim3 and uses thereof | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201804205UA (en) | Media mixing chamber |